SCHEMBL27030232

SCHEMBL27030232

COc1ccc(CNc2cc(Cl)ncc2C(C)=O)c(OC)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 2/20 0.57
MAPT P10636 2/20 0.51
TSHR P16473 7/20 0.47
ALDH1A1 P00352 6/20 0.47
NPSR1 Q6W5P4 1/20 0.47
CYP1A2 P05177 9/20 0.47
CYP3A4 P08684 9/20 0.47
CYP2D6 P10635 8/20 0.47
CYP2C19 P33261 8/20 0.47
CYP2C9 P11712 4/20 0.47
HSD17B10 Q99714 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
HIF1A Q16665 2/20 0.47
MAPK1 P28482 3/20 0.46
APLNR P35414 1/20 0.46
CLK4 Q9HAZ1 4/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
LMNA P02545 2/20 0.44
GLA P06280 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25703791 0.91 KDM4C (0.57) KDM4CMAPTTSHRALDH1A1NPSR1
SCHEMBL16993397 0.87 MAPT (0.65) KDM4CMAPTTSHRALDH1A1NPSR1
SCHEMBL30736062 0.83 KDM4C (0.60) KDM4CMAPTTSHRALDH1A1NPSR1
SCHEMBL22892765 0.83 NR3C1 (0.51) KDM4CMAPTMEN1KMT2A
SCHEMBL2478353 0.77 KDM4E (0.57) MAPTALDH1A1NPSR1LMNAL3MBTL1
SCHEMBL29552308 0.76 KDM4C (0.58) KDM4CMAPTTSHRALDH1A1NPSR1
SCHEMBL27007123 0.76 KDM4C (0.53) KDM4CMAPTTSHRALDH1A1NPSR1
SCHEMBL29922728 0.76 KDM4C (0.53) KDM4CMAPTTSHRALDH1A1NPSR1
SCHEMBL31280409 0.76 CYP1A2 (0.47) KDM4CMAPTTSHRALDH1A1CYP1A2
SCHEMBL2135922 0.76 KDM4C (0.52) KDM4CMAPTTSHRALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199613-A1 POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-06-20 US disclosed
EP-4308564-A1 POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN Takeda Pharmaceutical Company Limited (JP) 2024-01-24 EP disclosed
CN-117355523-A Polycyclic inhibitors of plasma kallikrein 武田药品工业株式会社 2024-01-05 CN disclosed
WO-2022197789-A1 POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2022-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199613-A1 POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN KLKB1, KLK1, KLK5 KDM4C 642/4885MAPT 3939/4885TSHR 4069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.